Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments

The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration

(2016) Sofia Anastasiadou et al.   EXPERIMENTAL NEUROLOGY

Brain Atrophy as a Measure of Neuroprotective Drug Effects in Multiple Sclerosis: Influence of Inflammation

(2016) Tatiana Koudriavtseva et al.   Frontiers in Human Neuroscience

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

(2015) Samuel F. Hunter et al.   CNS DRUGS

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis

(2015) Ludwig Kappos et al.   JOURNAL OF NEUROLOGY

Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration

(2015) Michael Deppe et al.   Multiple Sclerosis Journal

Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration

(2015) Michael Deppe et al.   Multiple Sclerosis Journal

FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway

(2014) Achilles Ntranos et al.   JOURNAL OF NEUROIMMUNOLOGY

Fingolimod phosphate promotes the neuroprotective effects of microglia

(2013) Hiromi Noda et al.   JOURNAL OF NEUROIMMUNOLOGY

Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice

(2013) Xiaojie Wang et al.   NMR IN BIOMEDICINE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis

(2011) S Rossi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

(2011) Jens Ingwersen et al.   CLINICAL IMMUNOLOGY

Measuring Myelin Repair and Axonal Loss with Diffusion Tensor Imaging

(2010) R.J. Fox et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Relationships of brain white matter microstructure with clinical and MR measures in relapsing-remitting multiple sclerosis

(2010) Antonio Giorgio et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

(2010) J. W. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Axial Diffusivity Is the Primary Correlate of Axonal Injury in the Experimental Autoimmune Encephalomyelitis Spinal Cord: A Quantitative Pixelwise Analysis

(2009) M. D. Budde et al.   JOURNAL OF NEUROSCIENCE

Human brain white matter atlas: Identification and assignment of common anatomical structures in superficial white matter

(2008) Kenichi Oishi et al.   NEUROIMAGE

Regional DTI differences in multiple sclerosis patients

(2008) S ROOSENDAAL et al.   NEUROIMAGE